Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Japan’s Peptide Door Receives ¥750 Million Investment From Tohoku Innovation Capital

This article was originally published in PharmAsia News

Executive Summary

Sentai, Japan-based Tohoku Innovation Capital has invested ¥750 million in Peptide Door Co., a biopharmaceutical venture company based in Takasaki, Japan, with core technology related to therapeutic peptides. Peptides allow the creation of peptide antibodies in animals without the need to purify the protein of interest, and it has received increasing attention from drug developers. Peptide Door currently is conducting joint research on a treatment for septicemia with other pharmaceutical companies. (Click here for more - Japanese language



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts